RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $81 to $79.
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $81 to $79.